GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » Earnings per Share (Diluted)

Shanghai HeartCare Medical Technology (HKSE:06609) Earnings per Share (Diluted) : HK$-2.70 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology Earnings per Share (Diluted)?

Shanghai HeartCare Medical Technology's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-1.15. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.70.

Shanghai HeartCare Medical Technology's EPS (Basic) for the six months ended in Dec. 2023 was HK$-1.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.70.

Shanghai HeartCare Medical Technology's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.89. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.45.

During the past 3 years, the average EPS without NRIGrowth Rate was 28.10% per year.

During the past 5 years, Shanghai HeartCare Medical Technology's highest 3-Year average EPS without NRI Growth Rate was 28.10% per year. The lowest was -39.00% per year. And the median was -5.45% per year.


Shanghai HeartCare Medical Technology Earnings per Share (Diluted) Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology Earnings per Share (Diluted) Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
-2.16 -6.52 -7.13 -5.85 -2.70

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only -4.24 -2.05 -3.90 -1.55 -1.15

Competitive Comparison of Shanghai HeartCare Medical Technology's Earnings per Share (Diluted)

For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai HeartCare Medical Technology's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai HeartCare Medical Technology's PE Ratio falls into.



Shanghai HeartCare Medical Technology Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Shanghai HeartCare Medical Technology's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-102.828-0)/38.077
=-2.70

Shanghai HeartCare Medical Technology's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-43.395-0)/38.014
=-1.14

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Shanghai HeartCare Medical Technology  (HKSE:06609) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Shanghai HeartCare Medical Technology Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai HeartCare Medical Technology (HKSE:06609) Business Description

Traded in Other Exchanges
N/A
Address
No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.
Executives
Ding Kui 2201 Interest of corporation controlled by you
Wisary Limited 2101 Beneficial owner
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology (HKSE:06609) Headlines

No Headlines